Fujifilm invests in Suono Bio to advance inflammatory-mediated disease pipeline — 3 insights

Fujifilm Corp. invested an undisclosed amount in Suono Bio to support the company's second-generation drug pipeline.

Here's what you should know:

1. Suono Bio is developing a series of therapies to treat inflammatory diseases.

2. Boston-based Brigham and Women's Hospital gastroenterologist Giovanni Traverso, MD, Polatis Partners Partner Amy Schulman and Carl Schoellhammer, PhD, founded the company.

3. Dr. Schoellhammer said, "I am thrilled that we have the opportunity to forge a long and fruitful relationship with Fujifilm to advance the development of our core technology. Their investment is a critical validation of our platform."

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers

Featured Podcast